Navigation Links
Cordex Pharma Forms Heart Failure Medical Advisory Board
Date:2/11/2009

molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which constitute novel therapeutic modalities for the treatment of major cardiovascular disorders. Cordex has a portfolio of investigational medicines, two of which are in late stages of clinical development. Cordex's ATPace is expected to enter a Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia in 2009. Cordex's CDP-1050 is also expected to commence a Phase 2 clinical trial for the treatment of heart failure in 2009. In addition, Cordex has a preclinical program to develop new chemical entities that target a recently discovered pathway in the pathophysiology of chronic obstructive pulmonary disease. For further information regarding Cordex, please visit the company's website at www.cordexpharma.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements. The forward-looking statements are based on current expectations, estimates and projections made by management. Cordex intends for the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," or variations of such words are intended to identify such forward-looking statements. All statements in this release regarding the future outlook related to Cordex are forward-looking statements, including, but not limited to, the statements regarding CDP-1050 as a paradigm for the treatment of heart failure, satisfaction of the medical community and regulatory authorities as to the
'/>"/>

SOURCE Cordex Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cordex Pharma Presents New Frontiers in Cardiovascular Medicines on January 29
2. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
3. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... 30, 2015 /CNW/ - A new national Labour Market ... and demographic profiles of new graduates entering the biotech ... Building Careers for New Grads in Biotech," is sponsored ... Pharmaceutical Companies (Rx&D) and features data collected from new ... subsidy program from 2013 to 2015. Among ...
(Date:3/30/2015)... PARK, N.J. , March 30, 2015 /PRNewswire/ ... (PAMORA) under development by Shionogi & Co., Ltd., ... phase III study (COMPOSE I) for the treatment ... chronic non-cancer pain receiving opioid therapy. Study results ... daily) statistically significantly improved the frequency of spontaneous ...
(Date:3/29/2015)... IRVING, Texas , March 29, 2015 ... the presentation of important study data showing ... cells in 1,599 gynecologic cancer samples. Using ... tumor profiling service, researchers identified expression of ... gynecologic cancers independent of histology while its ...
(Date:3/27/2015)... LANSING, Mich. , March 27, 2015  Neogen ... Properties, LLC, has adopted a prearranged trading plan in ... James Herbert , Chairman and CEO of Neogen Corporation, ... shares of Neogen Corporation common stock. Herbert ... the disclosure was appropriate. The filing is only for ...
Breaking Biology Technology:New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 2New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 3New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 4Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 2Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 4Neogen CEO adopts 10b5-1 Trading Plan 2
... and CLAREMONT, Calif., Jan. 18 /Xinhua-PRNewswire-FirstCall/ --,Kiwa ... KWBT),announced that it has held a meeting ... building the Company,s Distribution Network. Attendees included,representatives ... and provincial large volume agricultural products dealers., ...
... Corporation,(Nasdaq: ACEL ) today announced that it ... Scientific Protein Laboratories LLC (SPL) for the,commercial production ... is currently being evaluated as a treatment for,unresectable ... trial., "SPL has been involved in the ...
... Scientific studies on climate change, energy and alternative ... 145 million processing hours on supercomputers at Oak Ridge ... Novel Computational Impact on Theory and Experiment (INCITE) program. ... and government research facilities receive access to computing power ...
Cached Biology Technology:Kiwa Bio-Tech Products Group Holds Meetings to Build Distribution Network 2Kiwa Bio-Tech Products Group Holds Meetings to Build Distribution Network 3Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories 2Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories 3Oak Ridge leads DOE INCITE effort in 2008 2Oak Ridge leads DOE INCITE effort in 2008 3Oak Ridge leads DOE INCITE effort in 2008 4
(Date:3/19/2015)... OXFORD, Conn. , March 19, 2015  NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce market, ... featured in a news clip that aired this week on ... http://www.myfoxdc.com/ ) . In a segment "The Next ... smart wallet ,a new way to pay, and ,a really ...
(Date:3/17/2015)...  MecklerMedia Corporation (OTCQX: MECK) announced its ... ever held in New York City ... 2015 at the Javits Convention Center. ... Acorn Product Development; Axis NJ; c-Link Systems; CoroWare; ... NewBotic Corporation; Neya Systems LLC; Reliabotics; RoboKind; RocketFarm ...
(Date:3/12/2015)... Beta Systems today announced ... management (IAM) solution for a fixed price and ... new IAM package, customers benefit from the 30 ... IAM implementations across different industries. The new fixed-price ... any necessary services and consulting. It spans the ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2
... interdisciplinary perspective. Presenters at the National Academy of Sciences, ... ways to identify, encourage, and support advances in climate ... other fields. In addition, U.S. Secretary ... Sackler Lecture beginning at 6 p.m. on March 31 ...
... Providing further understanding of the link between low birth ... deprived newborns are "programmed" to eat more because they ... that controls food intake, according to an article published ... The study by a team of researchers at Los ...
... of people commit suicide worldwide each year, researchers and ... person,s likelihood of thinking about or trying to commit ... Hospital del Mar Research Institute (IMIM) has participated, has ... suicides. "It is of key importance to identify suicidal ...
Cached Biology News:Study provides explanation for connection between low birth weight and obesity later in life 2First international index developed to predict suicidal behavior 2
FGF Receptor 1 Antibody...
Rabbit polyclonal to Kallikrein 1 ( Abpromise for all tested applications). Antigen: Full length native kallikrein from tissue (Human) Entrez Gene ID: 3816 Swiss Protein ID: P06870...
EDG-1CT (endothelial cell differentiation gene-1, C terminal)...
Mouse monoclonal [1-N-14] to Adenovirus Type 7 hexon C11 Immunogen: Purified Adenovirus type 7 Specificity: This antibody is specific for Adenovirus type 7 hexon C11....
Biology Products: